Trizeptide and Retatrutide are investigational molecules for obesity treatment. Both are triple hormone receptor agonists that target glucose dependent insulinotropic polypeptide (GIP), glucagon like peptide 1 (GLP-1) and glucagon (GCG) receptors. They have shown promise in clinical trials for significant weight loss and metabolic health improvement.
A phase 2 clinical trial in The New England Journal of Medicine showed that Retatrutide achieved 17.5% mean weight loss at 24 and 48 weeks in obese and overweight adults. The phase 2 trial also showed that Retatrutide improved cardiometabolic markers: systolic and diastolic blood pressure, triglycerides, LDL-cholesterol, total cholesterol, HbA1c, fasting glucose and insulin at 24 and 48 weeks. A substudy found that Retatrutide reduced liver fat in patients with nonalcoholic fatty liver disease (NAFLD).
Trizeptide is also being studied for obesity and has shown similar results. Percentages of weight loss are still being evaluated but early trials suggest significant weight loss and metabolic health improvement.
Trizeptide and Retatrutide work by mimicking the action of natural hormones that regulate food intake, blood glucose, metabolism and energy expenditure. Triple hormone receptor agonist mechanism may be a more comprehensive approach to weight management compared to single hormone receptor agonists. These may also be beneficial for patients with chronic weight management, obstructive sleep apnea and liver disease.
Trizeptide and Retatrutide have shown more weight loss than other weight loss medications, semaglutide and tirzepatide. Their safety profile is similar to other incretin based therapies, with gastrointestinal side effects being the most common adverse events. They may have a better risk-benefit profile than bariatric surgery and other weight loss treatments.
The phase 2 clinical trial for Retatrutide was a 48 week, randomized, double blind, placebo controlled trial that enrolled 338 patients with obesity or overweight. Patients had a body mass index (BMI) ≥27 kg/m2 and were randomized to Retatrutide or placebo. The trial was conducted in the US and included patients with a range of weight related conditions, except type 2 diabetes.
Trizeptide trials are ongoing with similar designs in different populations with obesity and related conditions.
Both Trizeptide and Retatrutide were generally well tolerated, gastrointestinal side effects were the most common adverse events in study participants who treated with placebo group. The safety profile of both were similar to other incretin based therapies. There were no significant differences in serious adverse events between treatment and placebo groups while there have also been simultaneously published articles in yale obesity research center to conclude the same.
Future Directions
A larger phase 3 trial for Retatrutide is expected to be completed in December 2025 to further evaluate its efficacy and safety. Retatrutide may also be studied for liver disease and obstructive sleep apnea. Trizeptide is also moving to phase 3 trials, with ongoing research to fully explore its therapeutic potential.
Trizeptide and Retatrutide may be new options for patients with obesity and overweight who have not responded to other weight loss treatments. They may also reduce liver fat and improve metabolic health and may be useful for patients with NAFLD and other liver diseases. They may also have implications for prevention and treatment of weight related conditions such as type 2 diabetes and cardiovascular disease.
Clinical trials have shown patients can lose 12-24% of their body weight with Retatrutide, especially on the highest doses. Average weight loss is 12.9-17.3% depending on the highest dose used.
Retatrutide has shown more serious weight reduction and loss in clinical trials than Semaglutide. While Semaglutide works, Retatrutide’s triple hormone receptor agonist mechanism is a more comprehensive approach to weight management and results in higher both weight reduction and loss percentages in the studies.
Common side effects of Retatrutide are gastrointestinal related such as nausea, vomiting, diarrhea and constipation. These side effects are similar to other incretin based therapies.
While Retatrutide is being studied for weight loss, its mechanism of action includes GLP-1 receptor agonism so it may also be useful for glucose regulation in diabetics. But more research is needed to confirm its efficacy and safety for diabetes management.
As of now Retatrutide is still in investigational stage by the food and drug administration and and not available for public use. It is currently in phase 2 and 3 clinical trials and expected to be completed by December 2025.
Retatrutide targets three different hormone receptors (GIP, GLP-1 and glucagon) that control food intake, glucose metabolism, weight and energy expenditure. This holistic approach results to both significant improvements in weight loss and improved metabolic health.
Semaglutide can cause nausea, vomiting, diarrhea, constipation and abdominal pain. Some may also experience fatigue, headache and dizziness. Serious side effects are rare but can include pancreatitis and kidney problems.
Trizeptide and Retatrutide are investigational molecules that have shown weight loss and metabolic health improvement in clinical trials. Their triple hormone receptor agonist mechanism and good efficacy and safety side profile makes them a good addition to the treatment options for obesity and overweight. More research is needed to fully understand the benefits and risks but they can make a big impact on obesity and related conditions.
Disclaimer: Information on Peptide Hackers is for educational purposes only and not for medical advice. Consult with your medical officer or doctor before starting any new treatment. Use with caution as adverse events can happen and may lead to permanent treatment discontinuation. Do not compare treatments directly and for conditions like knee osteoarthritis additional diagnostic tools like MRI may be required. Always stay within the recommended dose to minimize risk and contact a healthcare professional for dose. Peptide Hackers is not liable for any outcome from the use of these products while you can buy Retatrutide but we only sell Retatrutide for research purposes only.
